Heat Biologics, Inc. (NASDAQ:HTBX) Presents Strong Momentum And Superior Growth

Taking into account all relevant factors, Heat Biologics, Inc. (NASDAQ:HTBX) scores 96% Sell on the technical side. The share price is also flashing a Sell from the Barchart TrendSpotter trading system. Investors starting out on a short-term path of investing should know that short terms indicators for HTBX averaged 75% Sell with an average daily trading volume over the past 20 days at 341792 shares. Those using medium-term investment strategies, the shares have overall a 1% Sell signal while the 50-day average daily volume remained almost 428973 shares. It’s also important to note that the stock, whose average daily volume over the 100 days as of this piece was 298376 shares, is signaling100% Sell for long term investors.

The stock is lingering around the initial support level of $0.42. After this, the following support is at the zone of $0.4. Up until the time the HTBX stock hit levels beyond the current one, bulls should have no alarm. In terms of its momentum, the stock’s RSI hit 27.29 on the daily chart, and this may be a cause for comfort. In case the price goes below $0.4 level on closing basis, there may be more profit booking with the stock growing weaker. Still, getting to the $0.46 level may cause a pull-back move approaching $0.48 mark.

Let’s take a glimpse at some insider activity at Heat Biologics, Inc. (NASDAQ:HTBX) and observe the pattern. The earliest insider trade happened on 03/23/2016. KHARITONOV MICHAEL gathered a total of 900 thousand shares of the firm at average share price of $0.75. The total amount for the purchase was set at $675 thousand. On completing this exchange, the Director account balance was 949.96 thousand shares. The stock lost -60 percent from that insider purchase. On 06/05/2014, Price Melissa, VP Clinical/Regulatory Affairs, did a purchase of 0.69 thousand shares at a price of $4.3 per share. This increased 2.98 thousand shares to the insider’s fortune and the stock experienced a -93.02 percent retreat in price since the news became public. This exchange saw 0.69 thousand shares get into the VP Clinical/Regulatory Affairs account. On 05/19/2014, CEO, 10% Owner Wolf Jeffrey Alan recorded a purchase transaction valued at $10.33 thousand. The purchase at $4.13 a share has added 2.5 thousand shares into the insider’s portfolio position. Meanwhile, shares price witnessed -92.74 percent decrease since the transaction reporting date. The company insider is left with 1.24 million shares remaining in the account. Belsky Paul, who works as Director at the company, performed a purchase of 2.5 thousand shares in a transaction worth $10.28 thousand. The acquisition recorded on 05/16/2014 was priced at $4.11 per share. The stock price plunged -92.7 percent since the transaction. Belsky Paul currently holds a stake of 47.19 thousand in HTBX stock which is worth $14.16 thousand after the insider buying.

In the recent trading session, Heat Biologics, Inc. (NASDAQ:HTBX) shares lost -32.5% or -0.14 points to reach at $0.3 with a heavy trading volume of 3.235 million shares. It opened the trading session at $0.455, the shares rose to $0.457 and dropped to $0.4155, the range by which the price of stock traded the whole session. The company now has a market cap of $15.91 million and currently has 36.16 million outstanding shares. Heat Biologics, Inc. (HTBX) stock has plunged -0.88 percent of market value in 21 trading days.

Stock analysts at ROTH Capital, assumed coverage of shares of Heat Biologics, Inc. (NASDAQ:HTBX) with Buy recommendation, according to their opinion released on June 20.

HTBX stock’s trailing 3-year beta is 1.97, meaning there will be a greater rate of return, although posing a higher risk. The part of a firm’s profit given to each outstanding share of regular stock was -$0.68 share in the trailing 52 weeks. The stock’s value fallen -7.37 percent year to date (YTD) compared to a decline of -68.12 percent in 52 week’s period. The firm’s shares are still trading -83.5 percent below its 1-year high of $1.80 and -15.14 percent down from 52-week low of $0.35. The average consensus ranking on the company is 2, on a ranging where 5 is equal to a consensus sell rating. In other words, the mean analyst recommendations are ranking this stock as a buy.

Heat Biologics, Inc. (HTBX) shares are trading at a P/E ratio of -0.62 times earnings posted in the trailing 12 months. The industry HTBX deals with has an average P/E of 25.19. Its P/B ratio is standing at 1.12X compared to the 11.59 industry average. It is additionally sporting a 5.21 on the Price-to-Sales ratio, compared to the industry’s P/S average of 2.83.

Past records have indicated that shares in Heat Biologics, Inc. declined on 8 different earnings reaction days and we have yet to see whether this trend will play out and remain in place when the company reports upcoming earnings. Investors will get the next hint of HTBX’s Q4 earnings on March 27. Analysts are predicting revenue to suffer decline of -57.2 percent to $880M in the financial fourth quarter, while EPS will soar by about 0 percent to -$0.15 per share. In the last quarter, it’s earnings of -$0.17 per share came worse than the -$0.16667, adjusted, expected by Thomson Reuters consensus estimate. Revenue for the quarter was $6440. Earnings are seen to rise by 82.6 percent this year, 26.7 percent in the coming year.